MA46585A - Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib - Google Patents

Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib

Info

Publication number
MA46585A
MA46585A MA046585A MA46585A MA46585A MA 46585 A MA46585 A MA 46585A MA 046585 A MA046585 A MA 046585A MA 46585 A MA46585 A MA 46585A MA 46585 A MA46585 A MA 46585A
Authority
MA
Morocco
Prior art keywords
trapping
treatment
methods
muscle atrophy
bone diseases
Prior art date
Application number
MA046585A
Other languages
English (en)
Inventor
Hq Han
Xiaolan Zhou
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA46585A publication Critical patent/MA46585A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA046585A 2016-10-20 2017-10-19 Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib MA46585A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410595P 2016-10-20 2016-10-20

Publications (1)

Publication Number Publication Date
MA46585A true MA46585A (fr) 2019-08-28

Family

ID=62019496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046585A MA46585A (fr) 2016-10-20 2017-10-19 Méthodes de traitement de l'atrophie musculaire et des maladies osseuses faisant appel à de nouvelles protéines hybrides piégeant le ligand d'actriib

Country Status (23)

Country Link
US (3) US20190330307A1 (fr)
EP (2) EP4714967A2 (fr)
JP (1) JP2019535675A (fr)
KR (1) KR20190071758A (fr)
CN (1) CN109922821A (fr)
AU (1) AU2017345435B2 (fr)
CA (1) CA3039066A1 (fr)
CL (1) CL2019001069A1 (fr)
CO (1) CO2019005115A2 (fr)
CR (1) CR20190247A (fr)
EA (1) EA201990971A1 (fr)
ES (1) ES3064852T3 (fr)
IL (1) IL266032B2 (fr)
JO (1) JOP20190085A1 (fr)
MA (1) MA46585A (fr)
MX (1) MX2019004651A (fr)
PE (1) PE20190743A1 (fr)
PH (1) PH12019500853A1 (fr)
SG (2) SG11201903450YA (fr)
TN (1) TN2019000119A1 (fr)
TW (1) TWI826358B (fr)
WO (1) WO2018075747A1 (fr)
ZA (1) ZA201903105B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
KR20170141215A (ko) 2015-04-06 2017-12-22 악셀레론 파마 인코포레이티드 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
KR102761094B1 (ko) 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
WO2018067879A1 (fr) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Hétéromultimères alk4:actriib et leurs utilisations
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN119241685A (zh) 2016-11-10 2025-01-03 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CN111801112A (zh) 2017-11-09 2020-10-20 科乐斯疗法公司 激活素受体iia型变体及其使用方法
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
WO2019217715A1 (fr) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
MX2022009553A (es) * 2020-02-03 2022-11-07 Acceleron Pharma Inc Proteínas actriib variantes y sus usos.
EP4121088A4 (fr) * 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Procédés d'utilisation de variants de récepteur de l'activine de type iib
WO2021189006A1 (fr) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Procédés d'utilisation de variants du récepteur de l'activine de type iia
CA3176735A1 (fr) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Chimeres de type ii du recepteur d'activine et leurs methodes d'utilisation
CN115427056A (zh) * 2020-04-13 2022-12-02 细胞基因公司 使用actriib配体陷阱和菲卓替尼治疗贫血的方法
EP4142769A4 (fr) 2020-04-28 2024-05-15 Acceleron Pharma Inc. Protéines actrii et leur utilisation dans le traitement de l'hypertension pulmonaire post-capillaire
WO2022150590A1 (fr) * 2021-01-08 2022-07-14 Acceleron Pharma Inc. Compositions et méthodes de traitement de l'hypertension pulmonaire
US20260092096A1 (en) * 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof
WO2026096847A1 (fr) * 2024-11-01 2026-05-07 Bristol-Myers Squibb Company Méthodes de régulation de l'inflammation et de l'autophagie à l'aide de pièges à ligands actriib

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
AU2012204098B2 (en) 2001-04-24 2014-05-15 The Johns Hopkins University Use of follistatin to increase muscle mass
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
WO2005047337A1 (fr) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. Composition pharmaceutique presentant une region de l'immunoglobuline fc comme excipient
EP3489257A1 (fr) * 2004-07-23 2019-05-29 Acceleron Pharma Inc. Polypeptides du récepteur actrii, procédés et compositions
AU2015200950B2 (en) 2004-07-23 2017-04-27 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
WO2008076437A2 (fr) 2006-12-18 2008-06-26 Acceleron Pharma Inc. Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8501678B2 (en) * 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
KR20110031951A (ko) 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
CN102131822A (zh) 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
NZ627111A (en) 2008-11-26 2015-10-30 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2993053A1 (fr) 2009-04-27 2010-11-04 Novartis Ag Anticorps anti-recepteur de l'activine iib (actriib) destines a augmenter la croissance musculaire
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (fr) * 2009-06-12 2020-09-02 Acceleron Pharma Inc. Protéines de fusion actriib-fc tronquées
CN102655872B (zh) 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
JP6211767B2 (ja) * 2009-09-09 2017-10-11 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
WO2011056896A1 (fr) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Procédés de traitement de la stéatose hépatique
EP3332796A1 (fr) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Protéines actriib et variants et leurs utilisations se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
US20110268736A1 (en) 2010-04-30 2011-11-03 Children's Medical Center Corporation Method for treating congenital myopathy
WO2012027065A2 (fr) 2010-08-27 2012-03-01 Celgene Corporation Polythérapie pour traiter des maladies
KR20140084211A (ko) 2011-10-17 2014-07-04 악셀레론 파마 인코포레이티드 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
BR112014015003A2 (pt) * 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2912462B1 (fr) 2012-10-24 2019-08-07 Celgene Corporation Biomarqueur utilisable dans le traitement de l'anémie
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
EP3119418B1 (fr) 2014-03-21 2022-02-23 Acceleron Pharma Inc. Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
BR112016024319B1 (pt) 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
MA41919A (fr) * 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
SI3286206T1 (sl) * 2015-04-22 2021-07-30 Biogen Ma Inc. Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
CA2996996A1 (fr) 2015-08-31 2017-03-09 National Research Council Of Canada Molecules de fusion d'ectodomaines du recepteur du tgf-b et leurs utilisations
EP3370754B1 (fr) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace
CA3005975A1 (fr) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methode de traitement de troubles oculaires
WO2017192847A1 (fr) * 2016-05-04 2017-11-09 University Of Cincinnati Thérapies de la fertilité femelle
KR20210082548A (ko) 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
KR102761094B1 (ko) * 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20200109330A (ko) * 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법

Also Published As

Publication number Publication date
IL266032B2 (en) 2024-06-01
AU2017345435B2 (en) 2021-11-11
TW201827069A (zh) 2018-08-01
EP3528833C0 (fr) 2025-12-24
US12187783B2 (en) 2025-01-07
SG11201903450YA (en) 2019-05-30
TN2019000119A1 (en) 2020-10-05
EP4714967A2 (fr) 2026-03-25
CL2019001069A1 (es) 2019-08-23
JOP20190085A1 (ar) 2019-04-17
JP2019535675A (ja) 2019-12-12
AU2017345435A1 (en) 2019-05-23
ES3064852T3 (en) 2026-04-29
CR20190247A (es) 2019-07-29
EP3528833B1 (fr) 2025-12-24
EA201990971A1 (ru) 2019-10-31
US20220332791A1 (en) 2022-10-20
TWI826358B (zh) 2023-12-21
IL266032B1 (en) 2024-02-01
CN109922821A (zh) 2019-06-21
EP3528833A4 (fr) 2020-11-25
EP3528833A1 (fr) 2019-08-28
MX2019004651A (es) 2019-10-09
CO2019005115A2 (es) 2019-05-31
US20190330307A1 (en) 2019-10-31
KR20190071758A (ko) 2019-06-24
ZA201903105B (en) 2023-03-29
IL266032A (en) 2019-06-30
US20250109183A1 (en) 2025-04-03
SG10201913301TA (en) 2020-03-30
CA3039066A1 (fr) 2018-04-26
PE20190743A1 (es) 2019-05-27
PH12019500853A1 (en) 2019-12-02
WO2018075747A1 (fr) 2018-04-26

Similar Documents

Publication Publication Date Title
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
MA51451A (fr) Compositions d'acides aminés et méthodes de traitement de maladies hépatiques
EP3716767A4 (fr) Méthodes et compositions pour le traitement de maladies rares
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3891175A4 (fr) Protéines modifiées et méthodes de traitement associées
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3411080A4 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
EP3429536A4 (fr) Traitement de l'ostéopénie et de l'ostéoporose et stimulation de la croissance osseuse
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
EP3775263A4 (fr) Compositions et méthodes de traitement de l'acné
EP3870203A4 (fr) Associations thérapeutiques de tdfrp et d'agents complémentaires et méthodes d'utilisation
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
EP3523281A4 (fr) Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
EP3651747A4 (fr) Compositions et méthodes de traitement de troubles oculaires
MA55375A (fr) Méthodes thérapeutiques de traitement de l'hépatite b
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3681508A4 (fr) Méthode et composition pour le traitement d'une infection virale
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3813828A4 (fr) Méthodes de traitement de l'agitation faisant appel à du chlorhydrate de dexmédétomidine
EP3256461C0 (fr) Dérivés d'urée et de sulfonamide utilisés en tant qu'inhibiteurs d'hélicase ddx3 humaine utiles dans le traitement de maladies virales
EP3849591A4 (fr) Méthodes et compositions pour traiter des maladies de la peau
EP3571310A4 (fr) Compositions et méthodes de diagnostic et de traitement des maladies peroxysomales
EP3541401A4 (fr) Traitement des infections et maladies des voies respiratoires au moyen de compositions de glutathion